Skip to content
    PIPR
    Earnings call· Mar 2026(Q1 FY26)

    PIPER SANDLER COMPANIES Q1 FY26 earnings call PIPR

    May 1, 2026 Source

    Executive summary

    Piper Sandler Q1 FY26 — Strong Start with Record Corporate Investment Banking Revenues

    Piper Sandler delivered a strong start to FY26, driven by record Corporate Investment Banking and Advisory revenues, alongside robust Equity Brokerage performance. The firm continues to invest in talent and expand its platform, while maintaining operating discipline and returning significant capital to shareholders. Management anticipates some moderation in certain revenue streams in Q2 due to market conditions and volatility, but remains confident in its long-term strategy.

    Highlights

    5
    • Adjusted net revenues reached $470 million, marking the tenth consecutive quarter of year-over-year growth.

    • Corporate Investment Banking achieved a first-quarter record with revenues of $324 million, up 30% year-over-year.

    • Advisory revenues were a first-quarter record of $251 million, up 16% year-over-year.

    • Equity Brokerage revenues hit a record $60 million, an 11% increase from the prior year, driven by higher volatility.

    • Returned an aggregate of $171 million to shareholders, including $101 million in dividends and $70 million in share repurchases.

    Concerns

    5
    • Public Finance revenues were $24 million, down 9% year-over-year.

    • Fixed Income revenues, while up 6% year-over-year to $50 million, experienced a slow start to Q2 due to geopolitical developments and volatility.

    • Non-compensation expenses increased 15% year-over-year to $86 million, partly due to an $8.5 million litigation-related expense.

    • Bank M&A announced deal pace was slower than anticipated in Q1, particularly for larger transactions.

    • Software M&A outlook is cautious due to AI disruption, valuation gaps, and slower large deal activity.

    Guidance & targets

    5
    CategoryTargetConfidence
    Advisory revenues
    similar to the first quarter
    high materiality
    Medium
    Corporate Financing revenues
    decline from a strong first quarter
    high materiality
    Medium
    Public Finance revenues
    improve modestly from the first quarter
    medium materiality
    Medium
    Equity Brokerage revenues
    decline from the record first quarter levels
    medium materiality
    Medium
    Compensation ratio
    within the low end of the range or just below
    high materiality
    High

    Segment performance

    6
    SegmentRevenueYoYQoQMargin
    Corporate Investment Banking
    Achieved a first quarter record, driven by robust corporate financing activity and solid contributions across advisory services. Health Care franchise produced an exceptionally strong quarter.
    $324M30%
    Advisory Services
    First quarter record, due to strong performance from health care and financial services, and contributions from Services, Industrials and Energy teams. Non-M&A advisory teams, including Debt Capital Markets Advisory, also contributed.
    $251M16%
    Corporate Financing
    Strong performance driven by a resilient equity underwriting market, led by the Health Care team, particularly biopharma companies.
    $73M122%
    Public Finance
    Revenues were balanced between governmental and specialty businesses. Pipelines are strong for future activity.
    Municipal negotiated transactions underwritten: 98Par value raised for clients: $3B
    $24M-9%
    Equity Brokerage
    Record first quarter revenues, driven by higher volatility and increased trading volumes in response to geopolitical events. Performance was broad-based across trading desks, including derivatives.
    $60M11%
    Fixed Income
    Negatively impacted by day-to-day volatility in March, which reduced regular client activity. Mitigation efforts included balance sheet restructuring trades in conjunction with bank M&A closings.
    $50M6%

    Operational metrics

    15
    Adjusted net revenues
    $470M10th consecutive quarter of YoY growth
    Q1 FY26

    Represents the firm's overall revenue performance for the quarter.

    Operating margin
    20%
    Q1 FY26

    Reflects the firm's profitability from operations.

    Adjusted diluted EPS
    $1
    Q1 FY26

    Adjusted earnings per share for the quarter.

    Compensation ratio
    61.6%down 90 bps YoY
    Q1 FY26

    Improved ratio driven by increased net revenues, reflecting operating discipline.

    Non-compensation expenses
    $86Mup 15% YoY
    Q1 FY26

    Includes an $8.5 million litigation-related expense.

    Non-compensation expenses (ex-litigation)
    $77.5Mup 4% YoY
    Q1 FY26

    Excluding the $8.5 million litigation expense, non-compensation costs increased due to higher underwriting expenses.

    Effective tax rate
    23.4%
    Q1 FY26

    Reduced by $7 million of tax benefits related to vesting of restricted stock awards.

    Effective tax rate (ex-benefits)
    30.8%
    Q1 FY26

    Effective tax rate excluding the benefits from restricted stock awards.

    Total capital returned to shareholders
    $171M
    Q1 FY26

    Aggregate amount returned through dividends and share repurchases.

    Dividends paid
    $101M
    Q1 FY26

    Total dividends paid, including quarterly and special cash dividends.

    Share repurchases
    $70M
    Q1 FY26

    Repurchases offset a significant portion of share count dilution from annual grants.

    Quarterly cash dividend per share
    $0.20up 14%
    Q2 FY26

    Board approved increase from previous quarterly dividend.

    Investment banking managing directors
    192highest in firm history
    Q1 FY26

    Reflects investment in talent and strengthening of product and sector teams.

    Equity, debt, preferred financings completed
    36
    Q1 FY26

    Total number of financings completed for corporate clients.

    Capital raised for corporate clients
    $14B
    Q1 FY26

    Total capital raised across equity, debt, and preferred financings.

    Deals & partnerships

    5
    U.S. Med Tech M&A marketRanked as top adviser based on number of announced deals.

    The Health Care franchise produced an exceptionally strong quarter, with results driven by med tech and biopharma teams.

    U.S. bank M&A marketRanked as #1 adviser based on deal value announced during the quarter.

    Financial Services group registered a strong quarter, closing several significant bank M&A transactions.

    U.S. M&A market (under $2 billion)Ranked as #2 adviser based on announced deals.

    Advisory revenues were a first quarter record, with strong performance across various sectors.

    U.S. M&A market (under $5 billion)Ranked as #3 adviser based on announced deals.

    Advisory revenues were a first quarter record, with strong performance across various sectors.

    Biopharma sectorRanked as #2 investment bank based on the number of book-run deals.

    Strong equity issuance for biopharma companies led by the Health Care team, which served as bookrunner on all 23 equity deals they priced.

    Risks & headwinds

    6
    Near-term macroeconomic uncertaintynear-term

    unquantified

    Mitigation: Core strategy unchanged, focused on advising clients with deep expertise and comprehensive capital market solutions.

    Timing of transactions influenced by market conditionsQ2 FY26

    unquantified

    Mitigation: Pipelines remain strong, but market conditions may delay transaction closings.

    Market volatility impacting Fixed Income businessQ1 FY26, continuing into Q2 FY26

    day-to-day volatility during March significantly reduced regular client activity

    Mitigation: Diversification of product capabilities and client relationships, capital-light model provided resiliency; completed balance sheet restructuring trades.

    Geopolitical developments keeping Fixed Income clients on the sidelinesQ2 FY26

    slow start to the second quarter

    Mitigation: Awaiting sustained reduction in market volatility for clients to re-engage.

    Software M&A slowdown due to AI disruption and valuation gapsFY26

    things are going to be slower, folks are going to be cautious, valuations are down

    Mitigation: Expectations are fairly cautious for Tech and Software business this year; market will work its way through the system.

    Slower pace of larger Bank M&A transactionsQ1 FY26

    a little slower than we anticipated

    Mitigation: Smaller transactions show decent volume; historically, activity has picked up later in the year.

    What to watch in Q2 FY26

    5

    Advisory revenues

    next quarter
    Current$251M
    Targetsimilar to Q1 FY26

    Why it matters

    Advisory is a key revenue driver, and its stability is important for overall firm performance.

    We expect second quarter advisory revenues to be similar to the first quarter.

    Q&A highlights

    7

    Has the upward trend in bank M&A slowed, and how is recent rate volatility impacting the Bank Hedging business in Fixed Income?

    Bank M&A announced deals were slower than anticipated in Q1, especially for larger transactions, though smaller deals show decent volume. The derivatives desk is busy with hedging conversations, but extreme volatility makes it challenging for clients to position, so actual activity isn't necessarily outside the norm.

    I do think it's a little slower than we anticipated. We announced a couple more transactions this week. So I would say we're seeing decent volume on some of the smaller transactions, just haven't seen the pace we were seeing on a little bit of the larger transactions.

    asked by James Yaro · answered by Chad Abraham

    2 min read7 chapters

    Detailed Narrative

    01

    Overall Q1 Performance and Strategic Focus

    Piper Sandler reported a strong start to 2026 with adjusted net revenues of $470 million, marking the tenth consecutive quarter of year-over-year growth. The firm achieved a 20% operating margin and adjusted EPS of $1. Management emphasized its core strategy of advising clients with deep expertise and providing comprehensive capital market solutions, while expanding its platform for continued growth and delivering strong margins to shareholders.

    02

    Corporate Investment Banking Highlights

    Corporate Investment Banking (CIB) achieved a first-quarter record with revenues of $324 million, representing a 30% year-over-year increase. This performance was driven by robust corporate financing activity and solid contributions across advisory services. The Health Care franchise, particularly med tech and biopharma teams, produced an exceptionally strong quarter, setting a new revenue high watermark. The Financial Services group also performed strongly, closing several significant bank M&A transactions.

    03

    Advisory Business Performance

    Advisory revenues reached a first-quarter record of $251 million, up 16% year-over-year, primarily due to strong performance in healthcare and financial services, with contributions from Services, Industrials, and Energy teams. The firm ranked as the #2 adviser in U.S. M&A for deals under $2 billion and #3 for deals under $5 billion. Non-M&A advisory teams, including Debt Capital Markets Advisory and Private Capital Advisory Group, also showed positive momentum and contributed meaningfully to growth.

    04

    Corporate Financing Activity

    Corporate Financing revenues were $73 million, a significant 122% increase from Q1 last year, benefiting from a resilient equity underwriting market. The firm completed 36 equity, debt, and preferred financings, raising $14 billion for corporate clients. Activity was led by the Health Care team, which served as bookrunner on all 23 equity deals they priced, demonstrating strong market share capture in biopharma equity issuance.

    05

    Public Finance and Equity Brokerage

    Public Finance generated $24 million in municipal financing revenues, down 9% year-over-year, but with strong pipelines for future activity. The Equity Brokerage business achieved record first-quarter revenues of $60 million, up 11% from the prior year, driven by higher volatility and increased trading volumes across various desks, including derivatives, in response to geopolitical events.

    06

    Fixed Income Business Challenges

    The Fixed Income business produced $50 million in revenues, up 6% year-over-year, but was negatively impacted by extreme market volatility🌐 during March, which reduced regular client activity. The firm mitigated this through balance sheet restructuring trades linked to bank M&A closings. Management noted a slow start to Q2 for Fixed Income, with ongoing geopolitical developments keeping clients on the sidelines, indicating a challenging near-term outlook.

    07

    Talent and Capital Allocation

    Piper Sandler ended the quarter with 192 investment banking managing directors, a firm record, reflecting continued investment in talent through internal promotions and strategic external hires. The firm returned $171 million to shareholders in Q1, including $101 million in dividends and $70 million in share repurchases. The Board approved a 14% increase in the quarterly cash dividend to $0.20 per share, underscoring a commitment to shareholder returns and capital-light operations.

    AI-generated summary of the company’s earnings call. Not investment advice.